Evidence before advertising
Peptide Research
Molecule pages focused on evidence quality, U.S. regulatory status, and what is still unknown. None of these compounds is an FDA-approved treatment, and none is available through this site.
Molecule profiles(19)
- Recovery & RepairIn review
BPC-157: Research, FDA Status & What We Know
An evidence-focused guide to BPC-157, why it is discussed in recovery research, what human evidence is missing, and where its U.S. regulatory review stands.
FDA approval: Not FDA-approved
Reviewed September 2, 2026
- Metabolism & PerformanceIn review
CJC-1295: Research, FDA Status & What We Know
A review of CJC-1295 research, the DAC naming problem, human GH and IGF-1 findings, reported safety signals, and where its U.S. regulatory review stands.
Human evidence: Early pharmacology: small, short studies in healthy adults; no demonstrated clinical benefit
Reviewed September 14, 2026
- Sleep & RecoveryIn review
DSIP / Emideltide: Research, FDA Status & What We Know
A review of delta sleep-inducing peptide, also called emideltide in FDA materials, including the limits of sleep research and its 2026 U.S. compounding review.
FDA approval: Not FDA-approved
Reviewed September 2, 2026
- Brain & MoodIn review
Dihexa: Research, FDA Status & What We Know
A review of Dihexa’s cognitive-research findings, proposed neuroplasticity pathways, the research-integrity notices on key papers, and its current FDA status.
FDA approval: Not FDA-approved
Reviewed September 11, 2026
- Women’s HealthIn review
ENDO-205: A New Way of Thinking About Endometriosis
Why ENDO-205 is being studied as a non-hormonal, lesion-directed endometriosis therapy—and what its FDA IND clearance does and does not mean for patients.
FDA status: IND cleared; not approved
Reviewed September 14, 2026
- Sleep & LongevityIn review
Epitalon: Research, FDA Status & What We Know
A careful review of Epitalon research, longevity claims, sleep-related studies, evidence gaps, and the current U.S. compounding review.
FDA approval: Not FDA-approved
Reviewed September 2, 2026
- Skin, Hair & Healthy AgingIn review
GHK-Cu: Research, FDA Status & What We Know
A route-aware review of GHK-Cu research in skin and tissue biology, including the difference between cosmetic discussion, compounded products, and FDA drug approval.
FDA approval: No FDA-approved drug for promoted uses
Reviewed September 2, 2026
- Antioxidant & Cellular HealthIn review
Glutathione: Research, FDA Status & What We Know
An evidence-focused look at glutathione’s established biological role, the difference between endogenous function and marketed treatment claims, and why route and product quality matter.
FDA approval: Biological compound; claims and routes vary
Reviewed September 2, 2026
- Metabolism & PerformanceIn review
Ipamorelin: Research, FDA Status & What We Know
A review of Ipamorelin research, reported sleep and recovery experiences, what the small human studies measured, safety limits, and its FDA compounding status.
FDA approval: Not FDA-approved
Reviewed September 14, 2026
- Gut & InflammationIn review
KPV: Research, FDA Status & What We Know
What laboratory and preclinical research suggests about KPV, what has not been established in people, and how FDA’s 2026 compounding review affects the conversation.
FDA approval: Not FDA-approved
Reviewed September 2, 2026
- Immune & Host DefenseIn review
LL-37: The Human “First-Line Defense” Peptide
Why users call LL-37 a first-line defense peptide, what they report at the onset of illness, and what biofilm, immune, wound and FDA research actually shows.
FDA approval: Not FDA-approved
Reviewed September 11, 2026
- Metabolism & PerformanceIn review
MOTS-c: Research, FDA Status & What We Know
What early research says about MOTS-c, mitochondrial signaling, exercise and metabolism—and what has not been proven as a treatment.
FDA approval: Not FDA-approved
Reviewed September 2, 2026
- Skin, Hair & Healthy AgingIn review
Melanotan II: Effects, Risks & What the Evidence Shows
An evidence-focused guide to Melanotan II, online user reports, documented safety signals, FDA status, and why new or changing moles require medical review.
FDA approval: Not FDA-approved for tanning or any human use
Reviewed September 11, 2026
- Recovery & RepairIn review
PEG-MGF: Muscle-Recovery Claims vs. Human Evidence
What PEG-MGF is, why lifters discuss it for muscle recovery, what the laboratory research found, what human evidence is missing, and its current FDA status.
FDA approval: Not FDA-approved
Reviewed September 12, 2026
- Brain & MoodIn review
Selank: Research, FDA Status & What We Know
A neutral review of Selank, anxiety and stress-related research, the limitations of non-U.S. evidence, and the absence of FDA approval.
FDA approval: Not FDA-approved in the U.S.
Reviewed September 2, 2026
- Brain & MoodIn review
Semax: Research, FDA Status & What We Know
A U.S.-focused review of Semax research, cognitive and neurological claims, evidence limitations, and FDA’s 2026 compounding evaluation.
FDA approval: Not FDA-approved
Reviewed September 2, 2026
- Sleep & RecoveryIn review
Sermorelin: Sleep, Recovery & Growth Hormone Research
Why people discuss sermorelin for sleep, recovery and energy, what the human research found, and how its withdrawn FDA approvals differ from current compounded use.
FDA approval: No currently approved product
Reviewed September 12, 2026
- Recovery & RepairIn review
TB-500: Research, FDA Status & What We Know
A neutral review of TB-500, its relationship to thymosin beta-4 research, the limits of available human evidence, and its current U.S. regulatory status.
FDA approval: Not FDA-approved
Reviewed September 2, 2026
- Metabolism & PerformanceIn review
Tesamorelin: Visceral Fat, FDA Status & What the Evidence Shows
An evidence-focused guide to tesamorelin, visceral fat, reported experiences, its narrow FDA-approved indication, safety monitoring, and the clinical research.
FDA approval: Yes—for a specific HIV indication only
Reviewed September 12, 2026
Research guides and comparisons
Primers and head-to-head comparisons that answer the questions readers bring to the individual profiles.
- In review
BPC-157 vs. TB-500: What the Research Actually Compares
A side-by-side look at why BPC-157 and TB-500 are discussed together, how their research backgrounds differ, what is missing from human evidence, and why the “Wolverine Stack” is not a clinical protocol.
BPC-157: Mostly preclinical evidence
Reviewed September 2, 2026
- In review
Semax vs. Selank: Research Differences, Evidence Gaps & U.S. Status
A neutral comparison of Semax and Selank research, why cognition and stress claims are often grouped together, where the evidence is limited, and why neither should be positioned as a replacement for psychiatric care.
Semax: Limited, largely non-U.S. evidence
Reviewed September 2, 2026
- In review
What Are Peptides? A Research and Regulatory Primer
A plain-language guide to approved peptide medicines, compounded products, investigational compounds, research chemicals, evidence quality, and the role GLP-1 medications play in the broader peptide category.
Scope: Approved medicines + investigational research
Reviewed September 2, 2026